Who
Donald Allen Williams
Director
Company insider
Files Form 4 as: Director, Palisade Bio; Director, Forte Biosciences; Director, Alphatec Holdings; Director, Marina Biotech; Director, Akari Therapeutics.
In numbers
- Trades disclosed
- 56
- Buys
- 9
- Sells
- 0
- Bought
- $103K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 15 Sep 2014
- Last trade
- 2 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 5 Oct 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $15K10,000 at $1.46 | filing |
| 1 Oct 2026filed 5 Oct 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $14K10,000 at $1.42 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code A | —1,498,900 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —60,666 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —60,666 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —60,666 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code A | —1,498,900 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —60,666 | filing |
| 16 Jan 2026filed 21 Jan 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $8,3565,000 at $1.67 | filing |
| 16 Jan 2026filed 21 Jan 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $8,3505,000 at $1.67 | filing |
| 9 Jan 2026filed 13 Jan 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $9,4005,000 at $1.88 | filing |
| 9 Jan 2026filed 13 Jan 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $9,4005,000 at $1.88 | filing |
| 6 Oct 2025filed 6 Nov 2025 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —182,000 at $0.00 | filing |
| 6 Oct 2025filed 8 Oct 2025 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —1,538,700 at $0.00 | filing |
| 4 Sep 2025filed 5 Sep 2025 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —64,400 at $0.00 | filing |
| 21 Nov 2024filed 22 Nov 2024 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —388 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 Jul 2024filed 15 Jul 2024 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —2,100 at $0.00 | filing |
| 11 Jun 2024filed 12 Jun 2024 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —340 at $0.00 | filing |
| 28 May 2024filed 29 May 2024 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $4,8601,000 at $4.86 | filing |
News
Palisade Bio (NASDAQ:PALI) Downgraded by Wall Street Zen to "Sell"PALI · themarketsdaily.com · 18 Oct 2026Palisade Bio's (PALI) Buy Rating Reiterated at HC WainwrightPALI · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Donald Allen Williams; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.